AMPH Earnings
Latest Revenue183.9M
Latest Net Income30.3M
| Period | EPS | Revenue | Net Income | Rev YoY | EPS YoY |
|---|
| Q2 2026 | $0.69 | 183.9M | 30.3M | +5.4% | +4.5% |
| Q1 2026 | $0.14 | 171.2M | 6.4M | +0.4% | -73.6% |
| Q4 2025 | $0.53 | 183.1M | 24.4M | -1.8% | -40.4% |
| Q3 2025 | $0.38 | 191.8M | 17.4M | +0.3% | -54.2% |
| Q2 2025 | $0.66 | 174.4M | 31.0M | -4.4% | -14.3% |
| Q1 2025 | $0.53 | 170.5M | 25.3M | -0.8% | -41.1% |
| Q4 2024 | $0.89 | 186.5M | 38.0M | +4.7% | +18.7% |
| Q3 2024 | $0.83 | 191.2M | 40.4M | +5.9% | -17.8% |
| Q2 2024 | $0.77 | 182.4M | 37.9M | — | — |
| Q1 2024 | $0.90 | 171.8M | 43.2M | — | — |
| Q4 2023 | $0.75 | 178.1M | 36.2M | — | — |
| Q3 2023 | $1.01 | 180.6M | 49.2M | — | — |
Amphastar Pharmaceuticals (AMPH) — Earnings